市場調査レポート

商品コード

肺動脈性肺高血圧症の2028年までの市場予測-薬剤、タイプ、投与経路、流通チャネル別の世界分析

Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs, Type, Route of Administration, and Distribution Channel

出版日: 2023年01月02日 | 発行: The Insight Partners

| ページ情報: 英文 174 Pages | 納期: 1～5営業日

価格

PDF (Single User License)

USD 4,550 716,761円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Site License)

USD 6,550 1,031,821円

レポートPDFを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 8,550 1,346,881円

レポートPDFを企業内すべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.53円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

肺動脈性肺高血圧症市場は、2021年の73億6,989万米ドルから2028年には108億8,908万米ドルに成長すると予測され、2022年から2028年までのCAGRは5.8%と推定されています。市場成長の背景には、肺動脈性肺高血圧症の発症率の高まりと、肺動脈性肺高血圧症治療薬の認可の増加があります。しかし、肺動脈性肺高血圧症の治療に使用される薬剤の副作用が市場成長の妨げとなっています。

肺動脈性肺高血圧症（PAH）は、肺の動脈における高血圧（高血圧）が原因で起こる、まれで進行性の疾患です。血管内の圧力上昇は、様々な理由による肺の小動脈の閉塞が原因である可能性があります。PAHの正確な原因は不明で、治療可能ですが、永久に治る病気ではありません。PAHは通常、30～60歳の女性が罹患します。

特許失効により、ジェネリック医薬品が肺動脈性肺高血圧症市場に参入し、製品ラインアップが多様化します。今後2030年までの7～8年間で、特許が切れた製品が出回ると予想されます。このことは、今後数年間、ジェネリック製剤会社にとって大きなチャンスとなるでしょう。ギリアド・サイエンシズ社のアンブリセンタン＋タダラフィルはPAHの治療に使われていますが、その特許は2027年12月11日に失効します。多くの製薬会社がすでに特許製品のジェネリック版の開発に取り組んでいることをCare Ratingsは発見しています。特許が切れた後は、ジェネリック医薬品が利用できるようになります。消費者は低価格の恩恵を受ける一方で、特許の保護を失うことで、製薬会社は競争の激化にさらされることになります。したがって、特許の失効は、予測期間中、ジェネリック医薬品メーカーが新しい市場に参入する機会を開くと予想されます。

さらに、過去20年間で、PAHを治療するための14のFDA承認済み治療法が登場したことは、この疾患が少人数の患者を対象とすることを考えると、大きな偉業であると考えられます。PAH治療薬の開発成功の鍵は、本疾患の病因となる遺伝的・分子的メカニズムの理解における多大な進歩にあります。このような認識の高まりとともに、治療戦略も血管収縮に焦点を当てた現在のパラダイムから進化し、多様化し続けるでしょう。臨床試験では、新しいデリバリーデバイスの臨床効果や、他の肺高血圧症や併用療法におけるその有用性が模索されています。これが、今後の臨床試験のスタンダードになると思われます。

投与経路に基づく洞察

投与経路に基づき、肺動脈性肺高血圧症市場は、経口、静脈内／皮下、吸入に区分されます。経口セグメントは2021年に最大の肺動脈性肺高血圧症市場シェアを占め、予測期間中に最も高いCAGRを記録すると予測されます。症候性で中等度から重度のPAHの治療に使用される経口投与薬には、シルデナフィルとエンドセリン（ET）受容体拮抗薬（ERA）、ボセンタンとシタキセンタン（sitaxsentan）、ボセンタンに比べてET受容体親和性が高いアブリスタン経口ET（A）受容体選択的ERAが含まれます。さらに、PAHの治療のための新しい経口薬として、マキテンタン、リオシグアト、トレプロスチニルがあります。アンブリセンタンは、エンドセリン受容体拮抗薬で、PAH（WHOグループ1）の治療に適応があり、臨床的な悪化を遅らせることができます。タダラフィルとの併用により、アンブリセンタンは、疾患進行およびPAH悪化による入院のリスクを低減し、運動能力を向上させることが適応となります。

北米の肺動脈性肺高血圧症市場は、予測期間において最大のシェアを占めました。同地域の市場成長は、肺動脈性肺高血圧症の高い有病率、政府およびメーカーによる取り組みに起因しています。米国の肺動脈性肺高血圧症市場は、地域市場の中で大きなシェアを占めています。米国におけるPAHの有病率は、稀な疾患であるにもかかわらず、はるかに高くなっています。米国肺協会によると、PAHは希少かつ進行性の疾患で、米国では毎年約500～1,000人が新たに診断されるとされています。また、同協会によると、PAH患者の15～20％は、遺伝子変異による遺伝性PAHであるとされています。

さらに、メーカーは医療従事者に情報やリソースを提供するために様々な取り組みを行っており、市場の成長を後押ししています。ユナイテッド・セラピューティクスが支援するPAHイニシアチブは、PAHに罹患した患者の治療において医療従事者を支援するためのリソースや情報を提供しています。また、米国肺高血圧科学レジストリは、患者集団の遺伝情報、生殖歴、環境暴露データを調査する米国初のPAH患者レジストリとして設立されました。このように、毎年診断されるPAHの症例数が増加していることや、メーカーによる取り組みが、肺動脈性肺高血圧症治療薬やその他の治療方法に対する需要を喚起し、米国における肺動脈性肺高血圧症市場の成長をさらに後押ししています。

カナダは、北米の肺動脈性肺高血圧症市場で2番目に大きなシェアを占めています。カナダは、肺動脈性肺高血圧症の有病率が高いです。PHAカナダによると、同国の人口約1万人が肺高血圧症（PH）に罹患していると推定されていますが、診断を受けているのは約5,000人となっています。カナダでは、肺高血圧症の進行を遅らせたり、症状を緩和するための限られた数の治療薬が承認されています。過去20年間で、カナダで承認されたPAHの治療薬は10種類に過ぎません。しかし、成人および小児のPAHを専門に治療するセンターは、全国にあります。さらに、European Respiratory Journalに掲載された研究（2022年）では、カナダのPAHコホートにおける1年、3年、5年生存率は、それぞれ89.2%、75.6%、56.0%であったと報告されました。このように、カナダのPAH患者さんは、長期的には死亡率が高いことが報告されています。

世界保健機関（WHO）、米国食品医薬品局（FDA）、米国希少疾患機関（NORD）などは、肺動脈性肺高血圧症市場に関するレポートを作成する際に参照した一次情報および二次情報の一部です。

調査対象範囲
インサイトパートナーズの調査報告書ガイダンス
市場セグメンテーション
- 肺動脈性肺高血圧症の世界市場- 薬剤別
- 肺動脈性肺高血圧症の世界市場-タイプ別
- 肺動脈性肺高血圧症の世界市場-投与経路別
- 肺動脈性肺高血圧症の世界市場-流通経路別
- 肺動脈性肺高血圧症の世界市場-地域別

第2章肺動脈性肺高血圧症市場-主要なポイント

第3章調査手法

対象範囲
2次調査
1次調査

第4章肺動脈性肺高血圧症市場- 市場情勢

PEST分析
- 北米PEST分析
- 欧州PEST分析
- アジア太平洋地域のPEST分析
- 中東・アフリカPEST分析
- 中南米PEST分析
専門家の見解

第5章肺動脈性肺高血圧症市場- 主な市場力学

市場促進要因
- 肺動脈性肺高血圧症の罹患率の増加
- 肺動脈性肺高血圧症治療薬の承認取得の増加
市場抑制要因
- 肺動脈性肺高血圧症の治療に使用される薬剤の副作用
市場機会
- 特許満了の増加により、手頃な価格でジェネリック医薬品を入手可能
- 医薬品の特許満了データ
今後の動向
- 肺動脈性肺高血圧症の治療薬開発のための臨床試験の増加
インパクト分析

第6章肺動脈性肺高血圧症市場- 世界分析

肺動脈性肺高血圧症の世界市場収益と予測・分析
肺動脈性肺高血圧症の世界市場：地域別予測・分析
主要プレイヤーの市場ポジショニング

第7章：肺動脈性肺高血圧症の世界市場-2028年までの収益と予測- 薬剤別

肺動脈性肺高血圧症市場の収益シェア（薬剤別）2021年・2028年（%）
エンドセリン受容体拮抗薬（ERA）
プロスタサイクリンおよびプロスタサイクリンアナログ
SGC刺激薬
Pde-5ディップスティック

第8章肺動脈性肺高血圧症の世界市場の分析と2028年までの予測-タイプ別

肺動脈性肺高血圧症の世界市場：タイプ別2021年・2028年（%）
ブランド品
ジェネリック医薬品

第9章肺動脈性肺高血圧症の世界市場- 収入と2028年までの予測- 投与経路別

肺動脈性肺高血圧症市場の収益シェア（投与経路別）2021年＆2028年（%）
経口剤
静脈内/皮下
吸入投与

第10章肺動脈性肺高血圧症の世界市場-2028年までの収益と予測- 流通チャネル別

肺動脈性肺高血圧症市場の収益シェア（流通チャネル別）2021年・2028年（%）
病院内薬局・クリニック
オンライン薬局
小売薬局

第11章肺動脈性肺高血圧症市場-2028年までの収益と予測- 地域別分析

北米
- 米国
- カナダ
- メキシコ
欧州
- 英国
- ドイツ
- フランス
- イタリア
- スペイン
- その他欧州
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- その他アジア太平洋地域
中南米
- ブラジル
- アルゼンチン
- その他の中南米地域
中東・アフリカ
- UAE
- サウジアラビア
- 南アフリカ
- その他中東・アフリカ地域

第12章肺動脈性肺高血圧症市場へのCOVID-19パンデミックの影響

北米
欧州
アジア太平洋地域
中南米
中東&アフリカ

第13章肺動脈性肺高血圧症市場- 業界情勢

肺動脈性肺高血圧症市場の成長戦略（%）
有機的な展開
インオーガニック開発

第14章企業プロファイル

Johnson & Johnson
Gilead Sciences Inc
United Therapeutics Corp
Bayer AG
Aerami Therapeutics Holdings Inc
Novartis AG
GSK Plc
Teva Pharmaceutical Industries Ltd
Lupin Ltd
Pfizer Inc

第15章付録

The Insight Partners について
用語解説

図表

List Of Tables

Table 1. Drugs Patents Expiration Data
Table 2. North America Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 3. North America Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 4. North America Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 5. North America Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 6. US Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 7. US Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 8. US Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 9. US Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 10. Canada Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 11. Canada Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 12. Canada Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 13. Canada Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 14. Mexico Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 15. Mexico Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 16. Mexico Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 17. Mexico Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 18. Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 19. Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 20. Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 21. Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 22. UK Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 23. UK Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 24. UK Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 25. UK Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 26. Germany Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 27. Germany Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 28. Germany Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 29. Germany Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 30. France Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 31. France Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 32. France Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 33. France Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 34. Italy Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 35. Italy Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 36. Italy Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 37. Italy Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 38. Spain Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 39. Spain Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 40. Spain Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 41. Spain Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 42. Rest of Europe Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 43. Rest of Europe Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 44. Rest of Europe Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 45. Rest of Europe Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 46. Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 47. Asia Pacific Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 48. Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 49. Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 50. China Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 51. China Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 52. China Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 53. China Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 54. Japan Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 55. Japan Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 56. Japan Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 57. Japan Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 58. India Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 59. India Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 60. India Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 61. India Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 62. South Korea Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 63. South Korea Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 64. South Korea Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 65. South Korea Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 66. Australia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 67. Australia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 68. Australia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 69. Australia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 70. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 71. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 72. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 73. Rest of Asia Pacific Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 74. South and Central America: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 75. South and Central America: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 76. South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
Table 77. South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel- Revenue and Forecast to 2028 (US$ Million)
Table 78. Brazil: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 79. Brazil: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 80. Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
Table 81. Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 82. Argentina: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 83. Argentina: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 84. Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
Table 85. Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 86. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 87. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 88. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration- Revenue and Forecast to 2028 (US$ Million)
Table 89. Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 90. Middle East & Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 91. Middle East & Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 92. Middle East & Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 93. Middle East & Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 94. UAE Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 95. UAE Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 96. UAE Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 97. UAE Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 98. Saudi Arabia Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 99. Saudi Arabia Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 100. Saudi Arabia Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 101. Saudi Arabia Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 102. South Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 103. South Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 104. South Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 105. South Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 106. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Drugs - Revenue and Forecast to 2028 (US$ Million)
Table 107. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Type - Revenue and Forecast to 2028 (US$ Million)
Table 108. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Route of Administration - Revenue and Forecast to 2028 (US$ Million)
Table 109. Rest of the Middle East and Africa Pulmonary Arterial Hypertension Market, by Distribution Channel - Revenue and Forecast to 2028 (US$ Million)
Table 110. Organic Developments in the Pulmonary Arterial Hypertension Market
Table 111. Inorganic Developments in the Pulmonary Arterial Hypertension Market
Table 112. Glossary of Terms

List Of Figures

Figure 1. Pulmonary Arterial Hypertension Market Segmentation
Figure 2. Pulmonary Arterial Hypertension Market - By Geography
Figure 3. Pulmonary Arterial Hypertension Market Overview
Figure 4. Prostacyclin and Prostacyclin Analogs Segment Held Largest Share by Drugs of Pulmonary Arterial Hypertension Market
Figure 5. Asia Pacific to Show Significant Growth During Forecast Period
Figure 6. Pulmonary Arterial Hypertension Market, by Geography (US$ Million)
Figure 7. Global Pulmonary Arterial Hypertension Market - Leading Country Markets (US$ Million)
Figure 8. Global Pulmonary Arterial Hypertension Market, Industry Landscape
Figure 9. North America: PEST Analysis
Figure 10. Europe: PEST Analysis
Figure 11. Asia Pacific: PEST Analysis
Figure 12. Middle East and Africa: PEST Analysis
Figure 13. South and Central America: PEST Analysis
Figure 14. Experts Opinion
Figure 15. Pulmonary Arterial Hypertension Market Impact Analysis of Drivers and Restraint
Figure 16. Global Pulmonary Arterial Hypertension Market- Revenue Forecast and Analysis - 2020 - 2028
Figure 17. Global Pulmonary Arterial Hypertension Market - By Geography Forecast and Analysis - 2022 - 2028
Figure 18. Market Positioning of Key Players in Pulmonary Arterial Hypertension Market
Figure 19. Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
Figure 20. Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. SGC Stimulators: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
Figure 25. Branded: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. Generics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
Figure 28. Oral: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. Inhalational: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
Figure 32. Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. Online Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. Retail Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. North America: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 36. North America Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. North America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 38. US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 39. Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 40. Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 41. Europe: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 42. Europe Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 43. Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 44. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 45. Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 46. France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 47. Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 48. Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 49. Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 50. Asia Pacific: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 51. Asia Pacific Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 52. China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 53. Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 54. India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 55. South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 56. Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 57. Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 58. South and Central America: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 59. South and Central America Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (US$ Million)
Figure 60. South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
Figure 61. Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 62. Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 63. Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 64. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Key Country - Revenue (2021) (US$ Million)
Figure 65. Middle East & Africa Pulmonary Arterial Hypertension Market Revenue and Forecast to 2028 (USD Million)
Figure 66. UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 67. Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 68. South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 69. Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
Figure 70. Impact of COVID-19 Pandemic in North America Country Markets
Figure 71. Impact of COVID-19 Pandemic in European Country Markets
Figure 72. Impact of COVID-19 Pandemic on Asia Pacific Country Markets
Figure 73. Impact of COVID-19 Pandemic in South and Central American Countries
Figure 74. Impact of COVID-19 Pandemic on Middle East and Africa Country Markets
Figure 75. Growth Strategies in the Pulmonary Arterial Hypertension Market (%)

Product Code: TIPRE00005221

The pulmonary arterial hypertension market is expected to grow from US$ 7,369.89 million in 2021 to US$ 10,889.08 million by 2028; it is estimated to grow at a CAGR of 5.8% from 2022 to 2028. The market growth is attributed to the growing incidence of pulmonary arterial hypertension and the rising approvals of pulmonary arterial hypertension drugs. However, the side effects of drugs used to treat pulmonary arterial hypertension hamper the market growth.

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder caused due to high blood pressure (hypertension) in the arteries of the lungs. The increased pressure in the vessels may be caused by an obstruction in the small arteries in the lung for various reasons. The exact cause of PAH is unknown and although treatable; there is no permanent cure for the disease. PAH usually affects women between the age of 30-60 years..

Patent expiry permits generic drugs to penetrate the pulmonary arterial hypertension market and diversify product offerings. Over the next seven-eight years till 2030, the patented products are expected to go off-patent. This would provide an enormous opportunity for generic formulation companies in the coming years. AMBRISENTAN + TADALAFIL drug by Gilead Sciences, Inc. is used to treat PAH, and its patent will be expired by December 11, 2027. Many pharma companies are already working to develop the generic version of patented products, finds Care Ratings. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to open an opportunity for generic drug manufacturers to enter a new market during the forecast period.

Moreover, over the past 20 years, the arrival of 14 FDA-approved therapies for treating PAH is seen as a major feat considering that this disease affects a small population. The key to success in developing PAH therapies has been the immense advances in understanding the genetic and molecular mechanisms that drive the pathogenesis of the disease. With the growing awareness, the treatment strategies will continue to evolve and diversify from the current paradigm focused on vasoconstriction. Clinical trials are exploring the clinical efficacy of novel delivery devices and their utility in other forms of pulmonary hypertension and combination therapies. This will be the standard for clinical trials in the future.

Route of Administration-Based Insights

Based on route of administration, the pulmonary arterial hypertension market is segmented into oral, intravenous/subcutaneous, and inhalational. The oral segment held the largest pulmonary arterial hypertension market share in 2021 and is anticipated to register the highest CAGR during the forecast period. Orally administered agents used for the treatment of symptomatic, moderate-to-severe PAH include sildenafil and the endothelin (ET) receptor antagonists (ERAs), bosentan and sitaxentan (sitaxsentan), and abrisentan oral ET(A) receptor-selective ERA, with higher ET receptor affinity than bosentan. Moreover, new oral drugs for treating PAH include macitentan, riociguat, and treprostinil. Ambrisentan is an endothelin receptor antagonist indicated for treating PAH; WHO Group 1 and delay clinical worsening. In combination with tadalafil, ambrisentan is indicated to reduce the risks of disease progression and hospitalization for worsening PAH, and to improve exercise ability..

The pulmonary arterial hypertension market in North America held the largest share in the forecast period. The market growth in the region is attributed to the high prevalence of pulmonary arterial hypertension and initiatives by the government and manufacturers. The US pulmonary arterial hypertension market holds a significant share of the regional market. The prevalence of PAH in the US is much higher, although it is a rare disease. According to the American Lung Association, PAH is a rare and progressive disorder that accounts for about 500-1,000 new cases being diagnosed each year in the US. Additionally, as per the same source, ~15-20% of PAH patients have heritable PAH caused by genetic mutations.

Further, manufacturers undergo various initiatives to provide information and resources to healthcare practitioners, fueling the market growth. The PAH Initiative supported by United Therapeutics provides resources and information to assist healthcare providers in treating patients affected by PAH. In addition, the United States Pulmonary Hypertension Scientific Registry was established as the first US PAH patient registry to investigate genetic information, reproductive histories, and environmental exposure data in a patient population. Thus, the rising cases of PAH diagnosed each year and initiatives undertaken by manufacturers fuel the demand for pulmonary arterial hypertension drugs and other treatment methods, further bolstering the pulmonary arterial hypertension market growth in the US.

Canada holds the second-largest share of the pulmonary arterial hypertension market in North America. Canada has a high prevalence of pulmonary arterial hypertension. According to the PHA Canada, it is estimated that ~10,000 population in the country are affected by pulmonary hypertension (PH), but ~5,000 have been diagnosed with it. A limited number of treatments are approved in Canada to slow the progression of PH and alleviate symptoms. Over the last two decades, only 10 PH-specific medical treatments have been approved in Canada for treating PAH. However, the centers specializing in treating PAH in adults and children are located across the country. Additionally, a study (2022) published in European Respiratory Journal reported that the 1-, 3- and 5-year survival rates in the Canadian PAH cohort were 89.2%, 75.6%, and 56.0%, respectively. Thus, PAH patients in Canada are reported to have a high death rate in the long term.

The World Health Organization (WHO), US Food and Drug Administration (FDA), and National Organization for Rare Disorders (NORD) are among the primary and secondary sources referred to while preparing the report on the pulmonary arterial hypertension market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the pulmonary arterial hypertension market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the global pulmonary arterial hypertension market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Global Pulmonary Arterial Hypertension Market - By Drugs
- 1.3.2 Global Pulmonary Arterial Hypertension Market - By Type
- 1.3.3 Global Pulmonary Arterial Hypertension Market - By Route of Administration
- 1.3.4 Global Pulmonary Arterial Hypertension Market - By Distribution Channel
- 1.3.5 Global Pulmonary Arterial Hypertension Market - By Geography

2. Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Pulmonary Arterial Hypertension Market - Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 North America PEST Analysis
- 4.2.2 Europe PEST Analysis
- 4.2.3 Asia Pacific PEST Analysis
- 4.2.4 Middle East and Africa PEST Analysis
- 4.2.5 South and Central America PEST Analysis
4.3 Experts Opinion

5. Pulmonary Arterial Hypertension Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Growing Incidence of Pulmonary Arterial Hypertension
- 5.1.2 Rising Approvals of Pulmonary Arterial Hypertension Drugs
5.2 Market Restraints
- 5.2.1 Side Effects of Drugs Used for Treatment of Pulmonary Arterial Hypertension
5.3 Market Opportunities
- 5.3.1 Availability of Generics at Affordable Costs Due to Growing Patent Expiration
- 5.3.2 Drugs Patents Expiration Data
5.4 Future Trend
- 5.4.1 Rising Clinical Trials for Drugs Development to Treat Pulmonary Arterial Hypertension
5.5 Impact analysis

6. Pulmonary Arterial Hypertension Market - Global Analysis

6.1 Global Pulmonary Arterial Hypertension Market Revenue Forecast and Analysis
6.2 Global Pulmonary Arterial Hypertension Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players

7. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

7.1 Overview
7.2 Pulmonary Arterial Hypertension Market Revenue Share, by Drugs 2021 & 2028 (%)
7.3 Endothelin Receptor Antagonists (ERAs)
- 7.3.1 Overview
- 7.3.2 Endothelin Receptor Antagonists (ERAs): Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Prostacyclin and Prostacyclin Analogs
- 7.4.1 Overview
- 7.4.2 Prostacyclin and Prostacyclin Analogs: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.5 SGC Stimulators
- 7.5.1 Overview
- 7.5.2 SGC Stimulators: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Pde-5 Dipsticks
- 7.6.1 Overview
- 7.6.2 Pde-5 Dipsticks: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

8. Global Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

8.1 Overview
8.2 Global Pulmonary Arterial Hypertension Market, by Type 2021 & 2028 (%)
8.3 Branded
- 8.3.1 Overview
- 8.3.2 Branded: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
8.4 Generics
- 8.4.1 Overview
- 8.4.2 Generics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

9. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

9.1 Overview
9.2 Pulmonary Arterial Hypertension Market Revenue Share, by Route of Administration 2021 & 2028 (%)
9.3 Oral
- 9.3.1 Overview
- 9.3.2 Oral: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.4 Intravenous/ Subcutaneous
- 9.4.1 Overview
- 9.4.2 Intravenous/ Subcutaneous: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
9.5 Inhalational
- 9.5.1 Overview
- 9.5.2 Inhalational: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

10. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

10.1 Overview
10.2 Pulmonary Arterial Hypertension Market Revenue Share, by Distribution Channel 2021 & 2028 (%)
10.3 Hospital Pharmacies and Clinics
- 10.3.1 Overview
- 10.3.2 Hospital Pharmacies and Clinics: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.4 Online Pharmacies
- 10.4.1 Overview
- 10.4.2 Online Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
10.5 Retail Pharmacies
- 10.5.1 Overview
- 10.5.2 Retail Pharmacies: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)

11. Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Geographic Analysis

11.1 North America: Pulmonary Arterial Hypertension Market
- 11.1.1 Overview
- 11.1.2 North America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
- 11.1.3 North America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
- 11.1.4 North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
- 11.1.5 North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
- 11.1.6 North America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.6.1 US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.6.1.1 Overview
    - 11.1.6.1.2 US: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.6.1.3 US: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.6.1.4 US: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.6.1.5 US: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.6.1.6 US: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.6.2 Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.6.2.1 Overview
    - 11.1.6.2.2 Canada: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.6.2.3 Canada: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.6.2.4 Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.6.2.5 Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.6.2.6 Canada: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.1.6.3 Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.6.3.1 Overview
    - 11.1.6.3.2 Mexico: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.1.6.3.3 Mexico: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.1.6.3.4 Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.1.6.3.5 Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.1.6.3.6 Mexico: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.2 Europe: Pulmonary Arterial Hypertension Market
- 11.2.1 Overview
- 11.2.2 Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
- 11.2.3 Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
- 11.2.4 Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
- 11.2.5 Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
- 11.2.6 Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
- 11.2.7 Europe: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  - 11.2.7.1 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.1.1 Overview
    - 11.2.7.1.2 UK: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.1.3 UK: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.2.7.1.4 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.2.7.1.5 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.2.7.1.6 UK: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.2.7.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.2.1 Overview
    - 11.2.7.2.2 Germany: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.2.3 Germany: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.2.7.2.4 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.2.7.2.5 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.2.7.2.6 Germany: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.2.7.3 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.3.1 Overview
    - 11.2.7.3.2 France: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.3.3 France: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.2.7.3.4 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.2.7.3.5 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.2.7.3.6 France: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.2.7.4 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.4.1 Overview
    - 11.2.7.4.2 Italy: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.4.3 Italy: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.2.7.4.4 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.2.7.4.5 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.2.7.4.6 Italy: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.2.7.5 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.5.1 Overview
    - 11.2.7.5.2 Spain: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.5.3 Spain: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.2.7.5.4 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.2.7.5.5 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.2.7.5.6 Spain: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.2.7.6 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.6.1 Overview
    - 11.2.7.6.2 Rest of Europe: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.2.7.6.3 Rest of Europe: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.2.7.6.4 Rest of Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.2.7.6.5 Rest of Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.2.7.6.6 Rest of Europe: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.3 Asia Pacific: Pulmonary Arterial Hypertension Market
- 11.3.1 Overview
- 11.3.2 Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
- 11.3.3 Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
- 11.3.4 Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
- 11.3.5 Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
- 11.3.6 Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
- 11.3.7 Asia Pacific: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  - 11.3.7.1 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.1.1 Overview
    - 11.3.7.1.2 China: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.1.3 China: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.3.7.1.4 China: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.3.7.1.5 China Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.3.7.1.6 China Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.3.7.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.2.1 Overview
    - 11.3.7.2.2 Japan: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.2.3 Japan: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.3.7.2.4 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.3.7.2.5 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.3.7.2.6 Japan: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.3.7.3 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.3.1 Overview
    - 11.3.7.3.2 India: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.3.3 India: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.3.7.3.4 India: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.3.7.3.5 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.3.7.3.6 India: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.3.7.4 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.4.1 Overview
    - 11.3.7.4.2 South Korea: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.4.3 South Korea: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.3.7.4.4 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.3.7.4.5 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.3.7.4.6 South Korea: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.3.7.5 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.5.1 Overview
    - 11.3.7.5.2 Australia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.5.3 Australia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.3.7.5.4 Australia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.3.7.5.5 Australia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.3.7.5.6 Australia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.3.7.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.6.1 Overview
    - 11.3.7.6.2 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.3.7.6.3 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.3.7.6.4 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.3.7.6.5 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.3.7.6.6 Rest of Asia Pacific: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.4 South and Central America Pulmonary Arterial Hypertension Market
- 11.4.1 Overview
- 11.4.2 South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
- 11.4.3 South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
- 11.4.4 South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
- 11.4.5 South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
- 11.4.6 South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
- 11.4.7 South and Central America: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  - 11.4.7.1 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.4.7.1.1 Overview
    - 11.4.7.1.2 Brazil: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.4.7.1.3 Brazil: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.4.7.1.4 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.4.7.1.5 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.4.7.1.6 Brazil: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.4.7.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.4.7.2.1 Overview
    - 11.4.7.2.2 Argentina: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.4.7.2.3 Argentina: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.4.7.2.4 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.4.7.2.5 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.4.7.2.6 Argentina: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.4.7.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.4.7.3.1 Overview
    - 11.4.7.3.2 Rest of South and Central America: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.4.7.3.3 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.4.7.3.4 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.4.7.3.5 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.4.7.3.6 Rest of South and Central America: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
11.5 Middle East & Africa Pulmonary Arterial Hypertension Market
- 11.5.1 Overview
- 11.5.2 Middle East & Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
- 11.5.3 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
- 11.5.4 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
- 11.5.5 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
- 11.5.6 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
- 11.5.7 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Country, 2021 & 2028 (%)
  - 11.5.7.1 UAE: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
    - 11.5.7.1.1 Overview
    - 11.5.7.1.2 UAE: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.5.7.1.3 UAE: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.5.7.1.4 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.5.7.1.5 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.5.7.1.6 UAE: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.5.7.2 Saudi Arabia: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
    - 11.5.7.2.1 Overview
    - 11.5.7.2.2 Saudi Arabia: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.5.7.2.3 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.5.7.2.4 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.5.7.2.5 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.5.7.2.6 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.5.7.3 South Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
    - 11.5.7.3.1 Overview
    - 11.5.7.3.2 South Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.5.7.3.3 South Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.5.7.3.4 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.5.7.3.5 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.5.7.3.6 South Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)
  - 11.5.7.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market Revenue and Forecasts to 2028 (US$ Million)
    - 11.5.7.4.1 Overview
    - 11.5.7.4.2 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 (US$ Million)
    - 11.5.7.4.3 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Drugs, 2019-2028 (US$ Million)
    - 11.5.7.4.4 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2028 (US$ Million)
    - 11.5.7.4.5 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2028 (US$ Million)
    - 11.5.7.4.6 Rest of the Middle East and Africa: Pulmonary Arterial Hypertension Market, by Distribution Channel, 2019-2028 (US$ Million)

12. Impact Of COVID-19 Pandemic on Pulmonary Arterial Hypertension Market

12.1 North America: Impact Assessment of COVID-19 Pandemic
12.2 Europe: Impact Assessment of COVID-19 Pandemic
12.3 Asia Pacific: Impact Assessment of COVID-19 Pandemic
12.4 South & Central America: Impact Assessment of COVID-19 Pandemic
12.5 Middle East & Africa: Impact Assessment of COVID-19 Pandemic

13. Pulmonary Arterial Hypertension Market - Industry Landscape

13.1 Overview
13.2 Growth Strategies in the Pulmonary Arterial Hypertension Market (%)
13.3 Organic Developments
- 13.3.1 Overview
13.4 Inorganic Developments
- 13.4.1 Overview

14. Company Profiles

14.1 Johnson & Johnson
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Gilead Sciences Inc
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 United Therapeutics Corp
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Bayer AG
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Aerami Therapeutics Holdings Inc
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Novartis AG
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 GSK Plc
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Lupin Ltd
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Pfizer Inc
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms

肺動脈性肺高血圧症の2028年までの市場予測-薬剤、タイプ、投与経路、流通チャネル別の世界分析

Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs, Type, Route of Administration, and Distribution Channel

目次

第1章イントロダクション

第2章肺動脈性肺高血圧症市場-主要なポイント

第3章調査手法

第4章肺動脈性肺高血圧症市場- 市場情勢

第5章肺動脈性肺高血圧症市場- 主な市場力学

第6章肺動脈性肺高血圧症市場- 世界分析

第7章：肺動脈性肺高血圧症の世界市場-2028年までの収益と予測- 薬剤別

第8章肺動脈性肺高血圧症の世界市場の分析と2028年までの予測-タイプ別

第9章肺動脈性肺高血圧症の世界市場- 収入と2028年までの予測- 投与経路別

第10章肺動脈性肺高血圧症の世界市場-2028年までの収益と予測- 流通チャネル別

第11章肺動脈性肺高血圧症市場-2028年までの収益と予測- 地域別分析

第12章肺動脈性肺高血圧症市場へのCOVID-19パンデミックの影響

第13章肺動脈性肺高血圧症市場- 業界情勢

第14章企業プロファイル

第15章付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

4. Pulmonary Arterial Hypertension Market - Market Landscape

5. Pulmonary Arterial Hypertension Market - Key Market Dynamics

6. Pulmonary Arterial Hypertension Market - Global Analysis

7. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

8. Global Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

9. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

10. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

11. Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Geographic Analysis

12. Impact Of COVID-19 Pandemic on Pulmonary Arterial Hypertension Market

13. Pulmonary Arterial Hypertension Market - Industry Landscape

14. Company Profiles

15. Appendix

肺動脈性肺高血圧症の2028年までの市場予測-薬剤、タイプ、投与経路、流通チャネル別の世界分析

Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drugs, Type, Route of Administration, and Distribution Channel

目次

第1章 イントロダクション

第2章 肺動脈性肺高血圧症市場-主要なポイント

第3章 調査手法

第4章 肺動脈性肺高血圧症市場- 市場情勢

第5章 肺動脈性肺高血圧症市場- 主な市場力学

第6章 肺動脈性肺高血圧症市場- 世界分析

第7章：肺動脈性肺高血圧症の世界市場-2028年までの収益と予測- 薬剤別

第8章 肺動脈性肺高血圧症の世界市場の分析と2028年までの予測-タイプ別

第9章 肺動脈性肺高血圧症の世界市場- 収入と2028年までの予測- 投与経路別

第10章 肺動脈性肺高血圧症の世界市場-2028年までの収益と予測- 流通チャネル別

第11章 肺動脈性肺高血圧症市場-2028年までの収益と予測- 地域別分析

第12章 肺動脈性肺高血圧症市場へのCOVID-19パンデミックの影響

第13章 肺動脈性肺高血圧症市場- 業界情勢

第14章 企業プロファイル

第15章 付録

List Of Tables

List Of Figures

Reasons to Buy:

Table Of Contents

1. Introduction

2. Pulmonary Arterial Hypertension Market - Key Takeaways

3. Research Methodology

4. Pulmonary Arterial Hypertension Market - Market Landscape

5. Pulmonary Arterial Hypertension Market - Key Market Dynamics

6. Pulmonary Arterial Hypertension Market - Global Analysis

7. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Drugs

8. Global Pulmonary Arterial Hypertension Market Analysis and Forecasts to 2028 - by Type

9. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Route of Administration

10. Global Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - by Distribution Channel

11. Pulmonary Arterial Hypertension Market - Revenue and Forecast to 2028 - Geographic Analysis

12. Impact Of COVID-19 Pandemic on Pulmonary Arterial Hypertension Market

13. Pulmonary Arterial Hypertension Market - Industry Landscape

14. Company Profiles

15. Appendix

第1章イントロダクション

第2章肺動脈性肺高血圧症市場-主要なポイント

第3章調査手法

第4章肺動脈性肺高血圧症市場- 市場情勢

第5章肺動脈性肺高血圧症市場- 主な市場力学

第6章肺動脈性肺高血圧症市場- 世界分析

第8章肺動脈性肺高血圧症の世界市場の分析と2028年までの予測-タイプ別

第9章肺動脈性肺高血圧症の世界市場- 収入と2028年までの予測- 投与経路別

第10章肺動脈性肺高血圧症の世界市場-2028年までの収益と予測- 流通チャネル別

第11章肺動脈性肺高血圧症市場-2028年までの収益と予測- 地域別分析

第12章肺動脈性肺高血圧症市場へのCOVID-19パンデミックの影響

第13章肺動脈性肺高血圧症市場- 業界情勢

第14章企業プロファイル

第15章付録